Trial Search Results
A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors
This is open-label, Phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors that will be conducted in 3 parts (dose escalation, expansion to solid tumors, and expansion to T cell lymphomas). Part 3 Expansion will be conducted at Stanford to further evaluate the safety and efficacy in patients with T-cell lymphomas.
Stanford is currently not accepting patients for this trial.
Lead Sponsor:
Trillium Therapeutics Inc.
Stanford Investigator(s):
Intervention(s):
- Drug: TTI-621
- Drug: TTI-621 plus Rituximab
- Drug: TTI-621 plus Nivolumab
Phase:
Phase 1
Eligibility
Inclusion Criteria:
1. Advanced measurable malignancy
2. Adequate hematologic status
3. Relapsed or are refractory following at least 2 prior systemic therapeutic attempts (1
prior systemic attempt for PTCL). For CTCL, extracorporal photochemotherapy (ECP) will
be considered a systemic therapy. Local radiation and topical agents are not systemic
therapies.
4. Adequate coagulation function
5. Adequate hepatic function
6. Adequate renal function
Exclusion Criteria:
1. Known, current central nervous system disease involvement or untreated brain
metastases
2. Allogeneic transplant within 30 days prior to the planned start of treatment or
subjects with active graft-vs-host disease with the exception of Grade 1 skin
involvement
3. History of hemolytic anemia or bleeding diathesis
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Elle (Hyunjin) Kim
650-387-4436
Not Recruiting